,
10 tweets,
5 min read
Read on Twitter
Apples to apples $ALLK data suggests little differentiation versus ligelizumab, when using the standard UAS7 scale rather than ALLK's self-concocted UCT. Cash of $4.8/sh with lockup expiry coming Jan 15, nice time to shoehorn "positive" data PR 
$ALLK continues to get hit, one of the rare biotechs that escaped the December slaughter and despite recent decline sports a $1.8B market cap. Showed no differentiation vs Xolair in the first data cut despite easier patient pop. lockup just expired, stock catching up to reality
The dermographism data was a big test for $ALLK given it's the most common form of physical urticaria. Xolair beats the 40% complete response reported by $ALLK today handily, not to mention it did so in a randomized study with more severe patients and used industry standard endpt
And yes, $ALLK definition of a CR is definitely not the standard definition, as @stevedoc22 also points out. They do have UAS7 data as the PR indicates but choose only to report their own UCT Ensor. Reminder these are open label studies with patient reported outcome endpoints.
Final nail in the coffin for the $ALLK data. They finally do release the standard UAS7 score in the Xolair failure population today- if AK002 was TRULY doing something differentiated, you would expect to see meaningful responses in this population given different MoA.
That thesis is blown up. $ALLK shows 9% UAS7 complete responder rate here. What is the comp in this population? The CSU guidelines recommend generic cyclosporine or TNFa (50%+ CR rate)- aaaai.org/Aaaai/media/Me…
Bottomline- inert 8 hour infusion for hives, competing with generics.
Bottomline- inert 8 hour infusion for hives, competing with generics.
For those asking about the 8 hour infusion $ALLK pharmaceutical-technology.com/comment/chroni…
Good luck trying to convince patients to try this, esp with this data
Good luck trying to convince patients to try this, esp with this data
$ALLK weak all day on volume but getting hit a bit more following the Jefferies note which suggests that UCT may not be the primary endpt in a pivotal. We've already seen how the data deteriorate dramatically when standard UAS7 is endpt, and is what NVS is using in lige Ph3s
$ALLK should PR their SM data tomorrow before the R&D day begins. Likely will compare it to midostaurin's data. The only issue with that is that it's no longer the benchmark, because $BPMC avapritinib is streets ahead to the point new SM players can't seem to enroll their trials
No response rates in today's $ALLK pr, nothing about serum tryptase or mast cells, just symptoms from an open label small n study. Continue to find new "creative" ways of reporting data
